26.03.2012 20:35 Uhr, Quelle: Wallstreet online

Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 Antibody

PARIS and TARRYTOWN, New York, March 26, 2012 /PRNewswire/ - New Data Presented at American College of Cardiology Meeting Demonstrate Reductions of 40% to 72% in LDL-Cholesterol in Patients on Statins - Sanofi and Regeneron Pharmaceuticals, …

Weiterlesen bei Wallstreet online